Ritter Alex R, Yildiz Vedat O, Koirala Nischal, Baliga Sujith, Gogineni Emile, Konieczkowski David J, Grecula John, Blakaj Dukagjin M, Jhawar Sachin R, VanKoevering Kyle K, Mitchell Darrion
Department of Radiation Oncology, The Ohio State University Wexner Medical Center, 410 W 10th Ave., Columbus, OH 43210, USA.
Department of Biomedical Informatics, Center for Biostatistics, Ohio State University, 1800 Cannon Dr., Columbus, OH 43210, USA.
Cancers (Basel). 2023 Nov 16;15(22):5447. doi: 10.3390/cancers15225447.
Despite recommendations for upfront total laryngectomy (TL), many patients with cT4a laryngeal cancer (LC) instead undergo definitive chemoradiation, which is associated with inferior survival. Sociodemographic and oncologic characteristics associated with TL utilization in this population are understudied.
This retrospective cohort study utilized hospital registry data from the National Cancer Database to analyze patients diagnosed with cT4a LC from 2004 to 2017. Patients were stratified by receipt of TL, and patient and facility characteristics were compared between the two groups. Logistic regression analyses and Cox proportional hazards methodology were performed to determine variables associated with receipt of TL and with overall survival (OS), respectively. OS was estimated using the Kaplan-Meier method and compared between treatment groups using log-rank testing. TL usage over time was assessed.
There were 11,149 patients identified. TL utilization increased from 36% in 2004 to 55% in 2017. Treatment at an academic/research program (OR 3.06) or integrated network cancer program (OR 1.50), male sex (OR 1.19), and Medicaid insurance (OR 1.31) were associated with increased likelihood of undergoing TL on multivariate analysis (MVA), whereas age > 61 (OR 0.81), Charlson-Deyo comorbidity score ≥ 3 (OR 0.74), and clinically positive regional nodes (OR 0.78 [cN1], OR 0.67 [cN2], OR 0.21 [cN3]) were associated with decreased likelihood. Those undergoing TL with post-operative radiotherapy (+/- chemotherapy) had better survival than those receiving chemoradiation (median OS 121 vs. 97 months; = 0.003), and TL + PORT was associated with lower risk of death compared to chemoradiation on MVA (HR 0.72; = 0.024).
Usage of TL for cT4a LC is increasing over time but remains below 60%. Patients seeking care at academic/research centers are significantly more likely to undergo TL, highlighting the importance of decreasing barriers to accessing these centers. Increased focus should be placed on understanding and addressing the additional patient-, physician-, and system-level factors that lead to decreased utilization of surgery.
尽管有建议进行 upfront 全喉切除术(TL),但许多 cT4a 喉癌(LC)患者却接受了根治性放化疗,这与较差的生存率相关。该人群中与 TL 使用相关的社会人口统计学和肿瘤学特征研究不足。
这项回顾性队列研究利用了国家癌症数据库中的医院登记数据,分析了 2004 年至 2017 年期间被诊断为 cT4a LC 的患者。患者按是否接受 TL 分层,比较两组患者和医疗机构的特征。分别进行逻辑回归分析和 Cox 比例风险分析,以确定与接受 TL 和总生存期(OS)相关的变量。使用 Kaplan-Meier 方法估计 OS,并使用对数秩检验比较治疗组之间的 OS。评估了 TL 使用随时间的变化情况。
共识别出 11149 名患者。TL 的使用率从 2004 年的 36% 增加到 2017 年的 55%。在多因素分析(MVA)中,在学术/研究项目(OR 3.06)或综合网络癌症项目(OR 1.50)接受治疗、男性(OR 1.19)和医疗补助保险(OR 1.31)与接受 TL 的可能性增加相关,而年龄 > 61 岁(OR 0.81)、Charlson-Deyo 合并症评分≥3(OR 0.74)和临床区域淋巴结阳性(OR 0.78 [cN1],OR 0.67 [cN2],OR 0.21 [cN3])与可能性降低相关。接受 TL 并术后放疗(±化疗)的患者比接受放化疗的患者生存率更高(中位 OS 分别为 121 个月和 97 个月;P = 0.003),并且在 MVA 中,与放化疗相比,TL + PORT 与较低的死亡风险相关(HR 0.72;P = 0.024)。
随着时间的推移,cT4a LC 的 TL 使用量在增加,但仍低于 60%。在学术/研究中心寻求治疗的患者接受 TL 的可能性显著更高,这凸显了减少进入这些中心的障碍的重要性。应更加关注理解和解决导致手术使用率降低的额外患者、医生和系统层面的因素。